Licence extension approved for Hycamtin

The licensed indications for Hycamtin (topotecan) have been extended to include the treatment of patients with relapsed small cell lung cancer for whom re-treatment with first-line therapies is not considered appropriate.

Approval for the licence extension was granted on the based of trials in patients with small cell lung cancer who had relapsed following first line therapy and for whom retreatment with intravenous chemotherapy was not considered appropriate. In these patients Hycamtin was shown to significantly improve median survival times.

Further information: Merck Pharmaceuticals, Harrier House, High Street, Yiewsley, West Drayton, Middlesex UB7 7QG. Tel: (01895) 452307.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more